Poxel Successfully Raises €17.7 Million in a Capital Increase
05/25/20, 6:03 AM
Money raised
€17 million
POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) (“Poxel”, or the “Company”), today announced the successful private placement of 2,358,483 new ordinary shares, each with a nominal value of €0.02 per share (the “New Shares”), reserved to a specified category of investors (the “Reserved Offering”). The gross proceeds of the Reserved Offering are €17,688,622.50 ($19.4 million).
Company Info
Additional Info
AccelFoods is an early-stage venture fund investing in consumer products.
We partner with entrepreneurs to bring innovative, high-quality food and
beverage products to the forefront of the industry and create the next
generation of enduring brands. With nearly $40m under management, we are
hands-on partners that work tactically with our founders to scale their
businesses quickly and smartly. We connect the dots within the broader food
& beverage ecosystem to provide unique access, share distinct expertise,
and build solid infrastructure.